MAIA Biotechnology MAIA Insider Ownership

Updated Oct 10, 2026

Across the past 12 months, open-market trades by MAIA Biotechnology insiders were all purchases, totaling $985,885 (783.7K shares).

• Counted by insider, open-market buying of MAIA stock in the past 12 months came from 7 insiders, with no insider selling.
• Among MAIA Biotechnology's insiders, Vlad Vitoc (Chief Executive Officer) was the largest open-market buyer over the past 12 months, purchasing $302,435 of stock (240K shares), most recently on September 14, 2026.
• Per Business Quant, MAIA insiders together hold 5.24Mn shares based on their latest Form 4 filings, up 5.18% from 4.98Mn shares at the end of Q2 2026 and up 18.70% from 4.41Mn shares at the end of Q3 2025.
• Indirect holdings, through trusts, partnerships, family members and other entities, make up 29.25% (1.53Mn shares) of MAIA Biotechnology's insider total, with the other 70.75% (3.71Mn shares) held directly.
• The insider holdings in MAIA Biotechnology belong to 7 insiders who have reported on Form 4 within the past two years.
• MAIA Biotechnology's top three insider holders by shares held are Stan Smith (Director, 1.53Mn shares), Ngar Yee Louie (Director, 1.25Mn shares) and Vlad Vitoc (Chief Executive Officer, 1.05Mn shares).
• The largest insider, Stan Smith, holds 29.25% of MAIA's insider total.
• Institutions accounted for 22.24% of MAIA's outstanding shares in Q2 2026, insiders about 8.62% per their latest Form 4 filings, and other investors, including the public, about 69.14%.
• Over the trailing 12 months, 9 insiders reported transactions in MAIA stock across 51 Form 4 filings.
• The insider data for MAIA reflects Form 4 filings through October 2, 2026.